Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.
Key PointsMultiple phase 3 trials for VK2735 are ongoing, with key results expected in 2027 to 2028.
Key PointsMultiple phase 3 trials for VK2735 are ongoing, with key results expected in 2027 to 2028.